BioSpace News Archive

Medical Technology Disruptors Panel includes Renovia’s leva® Digital Therapeutic, a novel approach for an underreported disorder affecting 20 million women in the U.S.

HealthWell Partners with the Lupus Foundation of America to Provide Financial Assistance to People with Lupus

Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the development of regenerative medicines to save lives, announced today that the Biomedical Advanced Research and Development Authority (BARDA) part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services executed options to add $10.4 million under contract # HH

Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today announced the addition of Dr. Lucio Iannone, Senior Director of Venture Investments at Leaps by Bayer, to its Board of Directors.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (“ADCL”), will provide its COVID-19 surveillance testing program to the Stony Brook University Seawolves men’s and women’s basketball teams

Applied Nanoscience Inc. (ANI), a nanotechnology-based air filtration performance company, today announced that construction of a pilot plant has begun in Downs, KS with direct participation of the Kansas Department of Commerce.

CHO Plus (www.CHO-Plus.com), an early-stage innovation company developing technology to vastly increase the productivity of cells used to manufacture therapeutic proteins, announced today that it has entered into a research collaboration agreement with Janssen Biotech, Inc. (Janssen), one of the Pharmaceutical Companies of Johnson & Johnson.

CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m. ET to review clinical data presented during the Plenary Scientific Session at the annual ASH Meeting and Exposition from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that it has entered into a license agreement with Clev

Menarini Ricerche, the R&D division of the Menarini Group, reported today the positive results of the pharmacodynamic assay demonstrating target engagement in the dose escalation part of the DIAMOND-01 trial (CLI24-001; clinicaltrials.gov identifier NCT03008187), a study investigating SEL24/MEN1703,